Pacific Biosciences of California, Inc., a health care company based in Menlo Park, United States, operates within the Life Sciences Tools & Services sector. The company is renowned for its innovative sequencing systems, which are designed to assist scientists in resolving genetically complex problems. Utilizing Single Molecule, Real-Time (SMRT) technology, Pacific Biosciences enables real-time analysis of biomolecules with single molecule resolution, positioning itself as a leader in the field of genomic research.
The company’s stock is publicly traded on the Nasdaq stock exchange, with its most recent closing price recorded at $1.81 on February 9, 2026. Over the past year, the stock has experienced moderate volatility, with a 52-week high of $2.73 on January 22, 2026, and a low of $0.85 on May 27, 2025. This range reflects the dynamic nature of the biotechnology sector and the market’s response to various factors influencing the company’s performance.
Financially, Pacific Biosciences presents a mixed picture. The company’s price-to-earnings (P/E) ratio stands at -1.08, indicating negative earnings. This metric suggests that the company is currently not generating profit, which is not uncommon in the biotechnology industry, where significant investments in research and development can precede profitability. Despite this, the company’s price-to-book (P/B) ratio is 15.225, suggesting that the market values the company significantly above its book value. This high P/B ratio may reflect investor confidence in the company’s future growth potential and its strategic position within the life sciences sector.
As of the latest updates, Pacific Biosciences has not disclosed any new public information in the past 24 hours. The most recent article related to the company appeared in a conference transcript from the JPMorgan Healthcare Conference on January 13, 2026. This indicates a period of relative quiet in terms of public communications, which may be typical for a company focused on long-term research and development projects.
With a market capitalization of approximately $555.51 million, Pacific Biosciences continues to play a significant role in the health care and life sciences industries. For more detailed information about the company’s offerings and strategic initiatives, stakeholders and interested parties are encouraged to visit the company’s official website at www.pacb.com .
In summary, Pacific Biosciences of California, Inc. remains a key player in the biotechnology field, leveraging its advanced SMRT technology to address complex genetic challenges. While the company faces the typical financial challenges of the sector, its market valuation suggests a strong belief in its future prospects and contributions to scientific advancements.
